195 related articles for article (PubMed ID: 34154584)
1. The use of ondansetron for the treatment of nausea in dogs with vestibular syndrome.
Foth S; Meller S; Kenward H; Elliott J; Pelligand L; Volk HA
BMC Vet Res; 2021 Jun; 17(1):222. PubMed ID: 34154584
[TBL] [Abstract][Full Text] [Related]
2. Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study.
Henze L; Foth S; Meller S; Twele F; Charalambous M; Kenward H; Elliott J; Pelligand L; Volk HA
J Vet Intern Med; 2022 Sep; 36(5):1726-1732. PubMed ID: 35906792
[TBL] [Abstract][Full Text] [Related]
3. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.
Kenward H; Elliott J; Lee T; Pelligand L
BMC Vet Res; 2017 Aug; 13(1):244. PubMed ID: 28814338
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate.
Burke JE; Hess RS; Silverstein DC
J Am Vet Med Assoc; 2021 Dec; 260(S1):S40-S45. PubMed ID: 34914630
[TBL] [Abstract][Full Text] [Related]
5. The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning.
Clark RF; Chen R; Williams SR; Johnson CL; Harchelroad F
J Toxicol Clin Toxicol; 1996; 34(2):163-7. PubMed ID: 8618249
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron is safe and effective for prehospital treatment of nausea and vomiting by paramedics.
Salvucci AA; Squire B; Burdick M; Luoto M; Brazzel D; Vaezazizi R
Prehosp Emerg Care; 2011; 15(1):34-8. PubMed ID: 21091329
[TBL] [Abstract][Full Text] [Related]
7. Use of Prophylactic Ondansetron with Intravenous Opioids in Emergency Department Patients: A Prospective Observational Pilot Study.
Culver MA; Richards EC; Jarrell DH; Edwards CJ
J Emerg Med; 2017 Nov; 53(5):629-634. PubMed ID: 28987314
[TBL] [Abstract][Full Text] [Related]
8. Tropisetron vs ondansetron for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomized double-blind, placebo-controlled study.
Argiriadou H; Papaziogas B; Pavlidis T; Parlapani A; Georgiou M; Papagiannopoulou P; Papaziogas T
Surg Endosc; 2002 Jul; 16(7):1087-90. PubMed ID: 12165828
[TBL] [Abstract][Full Text] [Related]
9. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Pater JL; Lofters WS; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
Ann Oncol; 1997 Feb; 8(2):181-5. PubMed ID: 9093728
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Nakagaki M; Barras M; Curley C; Butler JP; Kennedy GA
Support Care Cancer; 2017 Feb; 25(2):607-613. PubMed ID: 27738796
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT).
Ades S; Halyard M; Wilson K; Ashikaga T; Heimann R; Kumar S; Blackstock W
Support Care Cancer; 2017 May; 25(5):1503-1510. PubMed ID: 28032216
[TBL] [Abstract][Full Text] [Related]
12. Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting.
Polati E; Verlato G; Finco G; Mosaner W; Grosso S; Gottin L; Pinaroli AM; Ischia S
Anesth Analg; 1997 Aug; 85(2):395-9. PubMed ID: 9249120
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
Simino GP; Marra LP; Andrade EI; Acúrcio Fde A; Reis IA; De Araújo VE; Cherchiglia ML
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1183-94. PubMed ID: 27180992
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal ondansetron hydrochloride for intractable nausea and vomiting due to diabetic gastroparesis in a patient on peritoneal dialysis.
Amin K; Bastani B
Perit Dial Int; 2002; 22(4):539-40. PubMed ID: 12322834
[No Abstract] [Full Text] [Related]
15. No more than necessary: safety and efficacy of low-dose promethazine.
Moser JD; Caldwell JB; Rhule FJ
Ann Pharmacother; 2006 Jan; 40(1):45-8. PubMed ID: 16352779
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.
Wang X; Wang L; Wang H; Zhang H
Cell Biochem Biophys; 2015 Jun; 72(2):471-3. PubMed ID: 25567657
[TBL] [Abstract][Full Text] [Related]
17. Ondansetron for the prevention and treatment of nausea and vomiting following pediatric strabismus surgery.
Caron E; Bussières JF; Lebel D; Mathews S; Milot J; Jacob JL; Moride Y; Lortie L
Can J Ophthalmol; 2003 Apr; 38(3):214-22. PubMed ID: 12733689
[TBL] [Abstract][Full Text] [Related]
18. Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Tan J; Wang S; Liang X; Li CC; Zhang J; Zhao Z; Kong XR; Deng X; Peng L; Yang C
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28941006
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
Kaushal J; Gupta MC; Kaushal V; Bhutani G; Dhankar R; Atri R; Verma S
Singapore Med J; 2010 Nov; 51(11):871-5. PubMed ID: 21140114
[TBL] [Abstract][Full Text] [Related]
20. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
